GO Main Menu Go Main Contents Go Bottom Menu

CelltrionHealthcare

gnb show

MENU

Gnb close

Herzuma®

  • Herzuma® is an oncology mAb biosimilar developed by Celltrion and approved by FDA and EMA.

    Herzuma® image
    • Product Name : Herzuma®
    • INN : Trastuzumab
    • Indications : HER2-Positive Metastatic Breast Cancer, Early Breast Cancer(EBC), Metastatic Gastric Cancer(MGC)
    • Protein Type : Monoclonal antibody (mAb)
    • Mechanism of Action : It binds to the HER2 receptor overexpressed on the surface of breast cancer cells, as an antibody, to prevent the proliferation and rapid growth of breast cancer cells.
    • Drug Approval Status : Korea, USA, Europe, Japan, Brazil, etc.

    This product description is for medical and educational purposes only.
    They are not intended to promote PR or sales campaigns.
    For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.